GlassScriptPhysician profile
Ha J Chon
NPI 1649937574
$3,442.84
in general payments reported to CMS, 2019-2025
18 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 90% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $784 · 2024: $1,185 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,193 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.02 |
| Education | $249.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $916.09 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $594.83 | 2023-2025 | Tyvaso, Orenitram, Remodulin |
| Merck Sharp & Dohme LLC | $409.95 | 2023-2025 | Winrevair, Keytruda |
| Actelion Pharmaceuticals US, INC. | $279.50 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Astellas Pharma US INC | $276.38 | 2025 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $173.03 | 2023-2025 | Fasenra |
| Amgen INC. | $138.61 | 2024-2025 | Tavneos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2024 | Caplyta |
| Scpharmaceuticals INC. | $120.29 | 2025 | |
| Cmp Pharma, INC. | $66.90 | 2023 | Tadliq, Norliqva, Liqrev |
| Genzyme Corporation | $65.31 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.37 | 2024-2025 | Livtencity, Glassia |
| Viatris Specialty LLC | $58.16 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $57.55 | 2023-2025 | |
| Mylan Specialty L.P. | $38.62 | 2024 | Yupelri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $22.91 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Electromed, INC. | $17.67 | 2025 | Smartvest |
| Invivyd INC | $17.67 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ha Chon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.